Oxford, UK, 16 March 2019 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, held a cake sale at its Head Office in Oxford in support of Comic Relief’s Red Nose Day.
A day of fundraising including a cake sale, at which all members of the senior management team donned their red noses and deely boppers (which made the eating of the cakes quite a sight!), resulted in a total of £125 raised for Comic Relief’s good causes.
Professor Nick La Thangue, Chief Executive and Founder of Celleron Therapeutics commented:
“Celleron Therapeutics is delighted to show its support to Comic Relief and all the fantastic work it continues to do around the world. Our team has embraced the event fully and I am pleased to confirm that Celleron will match all the monies raised at today’s event, to extend our final contribution to £125.”
About Celleron Therapeutics
Celleron Therapeutics is a biopharma advancing a clinical and pre-clinical pipeline of precision therapies for different cancer indications. The company is a spin-out from Oxford University and located on the Oxford Science Park, UK. Celleron Therapeutics has built a proprietary platform around epigenetic control
and immune modulation, providing its drugs with a two-pronged attack on cancer. Celleron’s approach seeks to align the right drug with the right patient enabling a personalised approach to cancer therapy.
Celleron Therapeutics’ focus is on those cancers where there is still an unmet need for long-term disease control. It is hoped that not only will patients volunteering for our clinical trials benefit directly, but the results from these studies will ultimately allow the general use of more effective, safer medicines.
Our goal is not only to treat cancer, but improve quality of life during therapy by reduction of side effects.
Celleron has a global license partnership with Astra Zeneca and is also initiating new trials in China. The company secured investment in 2016 from a consortium of South Korean investors. For more information see
Download the press release here: